Pharma BD Deal Intelligence
The $185M upfront deal that produced the most commercially successful pharmaceutical product in a single year. Comirnaty generated $36B in 2021 revenue alone, validating mRNA as a platform technology. The 50/50 cost-sharing structure made Pfizer's risk-adjusted return effectively infinite.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer and BioNTech entered a co-development and co-commercialization agreement for BioNTech's mRNA COVID-19 vaccine candidates (BNT162 program). Pfizer paid $185M upfront ($72M cash + $113M equity investment) with up to $563M in milestone payments. Development costs were split 50/50, with Pfizer initially funding 100% and BioNTech repaying its share from commercialization. The resulting Comirnaty vaccine generated over $36B in 2021 revenue alone and remains the most commercially successful product of the alliance. Revenue has since normalized sharply from its pandemic peak: Pfizer's FY2025 total revenue was $62.6B (down 2% YoY), with declining COVID-19 product sales the primary driver as US vaccine recommendations narrowed. The franchise also carries a patent-liability overhang: a Dusseldorf court ruled in March 2025 that Pfizer/BioNTech infringed Moderna's mRNA patents and must account for Comirnaty profits and pay compensation (subject to appeal), with parallel US litigation ongoing.
100M US cases/yr · $75.0B Peak COVID Vaccine Market (2022)
COVID-19 is caused by SARS-CoV-2, a respiratory coronavirus spread via exhaled droplets and particles, including from asymptomatic carriers. Illness ranges from mild cold/flu-like symptoms to pneumonia, multi-organ involvement, and Long COVID. Older adults, immunocompromised, and those with underlying conditions are highest risk. Per CDC, ~1.2M US deaths as of June 2024.
COVID vaccine market peaked ~$75B (2022), normalized to ~$10B annually. Pfizer/BioNTech and Moderna dominate.
Pfizer paid $185M upfront ($72M cash + $113M equity) for BNT162 mRNA COVID vaccine co-development.
Comirnaty became highest-grossing vaccine in history. $36.8B in 2021, peaked at $37.8B in 2022.
Dusseldorf court ruled Pfizer/BioNTech violated Moderna's mRNA patents developing Comirnaty; defendants must estimate infringement profits and pay compensation. Subject to appeal; US litigation ongoing.
Comirnaty generated >$80B cumulative revenue. 400M+ US doses. 50/50 profit split. Transformed both companies.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / BioNTech SE (this deal) | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
| Pfizer Inc. / Seagen Inc. | 2023 | $43.0B | 77 |
← Browse all deals · How we score deals
More: 2020 deals · Pfizer Inc. deals · Infectious Disease deals